Clinical Trials Directory

Trials / Completed

CompletedNCT02422966

Paracetamol in Patent Ductus Arteriosus

Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
110 (actual)
Sponsor
Aziende Chimiche Riunite Angelini Francesco S.p.A · Industry
Sex
All
Age
25 Weeks – 31 Weeks
Healthy volunteers
Not accepted

Summary

The purpose of the study is to assess the efficacy and safety of paracetamol in comparison to ibuprofen in the treatment of patent ductus arteriosus (PDA) in preterm infants.

Detailed description

Although patency of the ductus arteriosus is essential for fetal circulation, the postnatal ductal closure is critical for postnatal circulatory adaptation. In premature infants the circulating prostaglandin levels are higher than at term, and respiratory difficulties may lead to a state of hypoxia, which contribute to the failure of the ductus closure. Recently, an incidental finding in one preterm infant led to look at paracetamol, one of the most common drugs available, as an alternative therapeutic approach to ductal closure. If paracetamol is proven to be effective, it could become the treatment of choice for the management of PDA, mainly due to its more favorable safety profile. Although the recent results available in the literature demonstrates an highly success rate in ductal closure with paracetamol, all case studies are not powered to show efficacy of paracetamol for PDA closure. Further prospective randomized-controlled trials are needed to evaluate the efficacy of paracetamol versus ibuprofen for the closure of PDA. If paracetamol is indeed proven to be effective, it could become the treatment of choice for the management of PDA, mainly due to its more favorable side effect profile. In order to test this hypothesis, a randomized, open label, parallel groups, comparator controlled, multicentre, prospective study is proposed.

Conditions

Interventions

TypeNameDescription
DRUGParacetamol
DRUGIbuprofen

Timeline

Start date
2015-12-01
Primary completion
2019-01-01
Completion
2019-04-01
First posted
2015-04-22
Last updated
2019-07-12

Locations

5 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT02422966. Inclusion in this directory is not an endorsement.